Patrick J. McGrath, MD

Board Certifications: 
Psychiatry
Accepting New Patients
Profile Headshot

Overview

Academic Appointments

  • Professor of Clinical Psychiatry

Dr. McGrath is a specialist in the clinical psychopharmacology of mood and anxiety disorders. He is currently Co-Director of the Depression Evaluation Service at the New York State Psychiatric Institute which conducts research into all aspects of the diagnosis and treatment of mood disorders. Special current research interests of Dr. McGrath's include pharmacogenetics, which is the effort to determine genetic determinants of response to antidepressant medications; brain imaging using positron emission tomography (PET) and functional magnetic ressonance imagaing (fMRI) to determine the biology of response to antidepressants; prediction of loss of response to antidepressant medication; and the effects of alcohol abuse and dependence on the response to antidepressants.

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Schedule an Appointment

Phone Appointments

New and Existing Patients:
212-351-5096

Location(s)

CUMC/Herbert Pardes Building of the New York State Psychiatric Institute
1051 Riverside Drive
New York, NY 10032
Primary

Credentials & Experience

Education & Training

  • Columbia University College of Physicians and Surgeons
  • Internship: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center

Board Certifications

  • Psychiatry
America's Top Doctor
NY Top Doctor

Research

Dr. McGrath's research has focussed on the clinical psychopharmacologic treatment of mood disorders, including anxiety and co-morbid substance use disorders such as alcoholism.

Major current projects include: A translational neuroscience study of combination of antidepressants to accelerate and enhance response; a preliminary trial of transdermal selegiline for bipolar depression.

Research Interests

  • Clinical Psychopharmacology of Mood Disorders

Grants

CHILDREN AT HIGH AND AT LOW RISK FOR DEPRESSION (Federal Gov)

Jul 1 2010 - Jan 31 2017

BIOSIGNATURES OF TREATMENT REMISSION IN MAJOR DEPRESSION (Federal Gov)

Sep 30 2010 - Jun 30 2016

CHILDREN AT HIGH AND AT LOW RISK FOR DEPRESSION (Federal Gov)

Jul 1 2010 - May 31 2016

THE ANTIDEPRESSANT ACTION OF KETAMINE: BRAIN CHEMISTRY AND SUSTAINING REMISSION (Federal Gov)

Jul 1 2011 - Apr 30 2016

CHILDREN AT HIGH AND AT LOW RISK FOR DEPRESSION (Federal Gov)

Jul 1 2010 - Jan 31 2016

CHILDREN AT HIGH AND AT LOW RISK FOR DEPRESSION (Federal Gov)

Jul 1 2010 - Apr 30 2015

CHILDREN AT HIGH AND AT LOW RISK FOR DEPRESSION (Federal Gov)

Jul 1 2010 - Jan 31 2014

DEVELOPING A PET BIOMARKER TO PREDICT RESPONSE IN TREATMENT-RESISTANT DEPRESSION (Federal Gov)

Sep 30 2009 - Aug 31 2013

TREATMENT RESISTANT DEPRESSION (Federal Gov)

Oct 1 1999 - Sep 28 2009

Selected Publications

  • McGrath PJ, Stewart JW, Quitkin FM, Chen Y, Alpert JE, Nierenberg AA, Fava M, Cheng J, Petkova E: A prospective study of predictors of relapse during fluoxetine treatment of major depression. American Journal of Psychiatry 2006;In Press
  • McGrath PJ, Stewart JW, Petkova E, Quitkin FM, Amsterdam JD, Fawcett J, Reimherr FW, Rosenbaum JF, Beasley CM: Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. Journal of Clinical Psychiatry 2000;61: 518-524
  • McGrath PJ, Nunes EV, Stewart JW, Goldman D, Agosti V, Ocepek-Welikson K, Quitkin FM: Imipramine treatment of alcoholics with primary depression. Archives of General Psychiatry 1996;53: 232-240